Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL22206792 | 0.98 | TSHR (0.32) | TSHRMAPK1HSD17B10TDP1THRB | |
| Hydrochloric Acid SCHEMBL134284 | 0.98 | THRB (0.34) | TSHRMAPK1HSD17B10TDP1THRB | |
| Fluoride SCHEMBL22206791 | 0.98 | TSHR (0.32) | TSHRMAPK1HSD17B10TDP1THRB | |
| Cyanide SCHEMBL22191188 | 0.94 | TSHR (0.30) | TSHRMAPK1HSD17B10TDP1 | |
| Acetic Acid SCHEMBL2788321 | 0.94 | TSHR (0.33) | TSHRMAPK1HSD17B10TDP1THRB | |
| SCHEMBL22206793 | 0.93 | PARP1 (0.30) | PARP1 | |
| SCHEMBL29082836 | 0.91 | — | — | |
| SCHEMBL29082823 | 0.90 | — | — | |
| SCHEMBL22190612 | 0.87 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL5673706 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-07 | — | — | US | claimed |
| US-12616738-B2 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | NOVO NORDISK A/S (DK) | 2026-05-05 | — | — | US | claimed |
| US-20260090969-A1 | COMPOSITIONS THAT PROTECT CELLS FROM OXIDATIVE AND MITOCHONDRIAL STRESS | Nuchido Limited (GB) | 2026-04-02 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-20250213549-A1 | COMPOSITION COMPRISING NICOTINAMIDE, NICOTINAMIDE PRECURSORS, NICOTINAMIDE METABOLITES OR COMBINATIONS THEREOF FOR PREVENTING OR REDUCING ONE OR MORE POST-ACUTE SYMPTOMS OF INFECTIOUS DISEASES | CONARIS RESEARCH INSTITUTE AG (DE) | 2025-07-03 | — | — | US | claimed |
| US-20250172571-A1 | Biosignatures for Fatigue Syndromes | LABORATORIUM M NUYTINCK (BE) | 2025-05-29 | — | — | US | claimed |
| CN-119936223-A | Metabolic marker for diagnosing or monitoring gastric cancer, screening method and application thereof | 武汉迈特维尔医学科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | claimed |
| WO-2007074406-A2 | FORMULATIONS FOR TREATMENT OF LIPOPROTEIN ABNORMALITIES COMPRISING A STATIN A STATIN AND A METHYLNICOTINAMIDE DERIVATIVE | PHARMENA NORTH AMERICA INC. (CA) | 2007-07-05 | — | — | WO | claimed |
| WO-2007023398-A2 | COMPOUNDS FOR PHOTOCHEMOTHERAPY | UNIVERSITE DE GENEVE (US) | 2007-03-01 | — | — | WO | claimed |
| CN-1905875-A | The use of quaternary pyridinium salts as vasoprotective agents | PHARMENA SP Z O O (PL) | 2007-01-31 | — | — | CN | claimed |
| US-20070021379-A1 | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | PHARMENA NORTH AMERICA INC. (CA) | 2007-01-25 | — | — | US | claimed |
| EP-1713480-A2 | THE USE OF QUATERNARY PYRIDINIUM SALTS AS VASOPROTECTIVE AGENTS | Pharmena Sp Zo.o. (PL) | 2006-10-25 | — | — | EP | claimed |
| WO-2006024545-A1 | FUSED BICYCLIC NATURAL COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP AND PARP-MEDIATED INFLAMMATORY PROCESSES | STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) | 2006-03-09 | — | — | WO | claimed |
| WO-2005067927-A2 | THE USE OF QUATERNARY PYRIDINIUM SALTS AS VASOPROTECTIVE AGENTS | PHARMENA SP Z O.O. (PL) | 2005-07-28 | — | — | WO | claimed |
| EP-1147086-B1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2005-03-30 | — | — | EP | claimed |
| EP-1147086-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | Technical University of Lodz (PL) | 2001-10-24 | — | — | EP | claimed |
| WO-2000040559-A1 | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | TECHNICAL UNIVERSITY OF LODZ (PL) | 2000-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090969-A1 | COMPOSITIONS THAT PROTECT CELLS FROM OXIDATIVE AND MITOCHONDRIAL STRESS | NLN, TFAM, CYP27B1 | TSHR 3400/4885MAPK1 2184/4885HSD17B10 1746/4885 |
| US-12616738-B2 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | SLC5A1, GLP1R, SLC5A2 | TSHR 2274/4885MAPK1 668/4885HSD17B10 3918/4885 |
| US-20070021379-A1 | Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | HMGCR, NAMPT, NNMT | TSHR 3818/4885MAPK1 2082/4885HSD17B10 288/4885 |
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | ACTR2, RPS6KB2, EPB41L2 | TSHR 3673/4885MAPK1 2139/4885HSD17B10 3672/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | TSHR 2407/4885MAPK1 1697/4885HSD17B10 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.